Summit Capital Management’s Lifecore Biomedical LFCR Stock Holding History

Summit Capital Management’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-98,362	Closed	-$1.15M	–	81
2015 Q3	$1.15M	Sell	98,362 -84,971	-46%	-$1.13M	0.56%	42
2015 Q2	$2.65M	Sell	183,333 -16,865	-8%	-$243K	1.13%	25
2015 Q1	$2.79M	Buy	200,198 +95	+0%	+$1.31K	1.13%	27
2014 Q4	$2.76M	Sell	200,103 -108,982	-35%	-$1.41M	1.04%	27
2014 Q3	$3.79M	Buy	309,085 +13,620	+5%	+$170K	1.34%	29
2014 Q2	$3.69M	Buy	+295,465	New	+$3.48M	1.32%	30

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

NIMC

NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Summit Capital Management's LFCR Position: Q4 2015 in Review

Summit Capital Management sold out of Lifecore Biomedical (LFCR) in Q4 2015, closing a stake of 98,362 shares — an estimated $1.15M sold.

Summit Capital Management first reported a position in LFCR in Q2 2014 and held it in 6 quarters. The position peaked at $3.79M in Q3 2014. 109 funds tracked by Wall St. Rank hold LFCR as of Q4 2015.

Summit Capital Management reported no remaining Lifecore Biomedical position as of Q4 2015 after selling out during the quarter.
Summit Capital Management sold 98,362 Lifecore Biomedical shares in Q4 2015, an estimated $1.15M.
Summit Capital Management first reported a position in Lifecore Biomedical in Q2 2014 and held it in 6 quarters.
Summit Capital Management's Lifecore Biomedical position peaked at $3.79M in Q3 2014.
109 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2015.

Based on Summit Capital Management's 13F filing for Q4 2015, filed 11 Feb 2016.